立華股份(300761.SZ):今年冰鮮產品將在去年基礎上翻番,達到3000萬隻
格隆匯8月8日丨立華股份(300761.SZ)在半年報業績交流會上表示,為滿足銷售端活轉鮮的變化趨勢,公司積極佈局黃羽雞屠宰產能。公司依託江蘇立華食品積累的冰鮮雞生產管理和銷售經驗,在湘潭、揚州、惠州、泰安、濰坊等一體化養雞子公司所在地佈局黃羽雞屠宰產能。目前,湘潭屠宰廠已投產,揚州屠宰廠正投入試運營,其餘屠宰廠將於今明兩年逐步投產,屠宰產品的比例將呈逐年較快增長的態勢,今年冰鮮產品將在去年基礎上翻番,達到3,000萬隻。隨着公司屠宰廠的陸續投運,公司冰鮮產品將更好地覆蓋長三角、珠三角、京津冀等核心區域市場,推動產業鏈縱向延伸。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.